Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 34104 | Other Identifier | Auckland UniServices Ltd. | |
| 2015/00205 | Other Identifier | National University Hospital Singapore | |
| U1111-1171-8056 | Other Identifier | Universal Trial Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National University Hospital, Singapore | OTHER |
| Auckland UniServices Ltd. | INDUSTRY |
| Institute for Human Development and Potential (IHDP), Singapore | OTHER |
Not provided
Not provided
Not provided
Not provided
The study aims to assess whether a nutritional drink taken before conception and continuing through pregnancy, assists in the maintenance of healthy glucose metabolism in the mother and promotes offspring health.
It is known that maternal insulin resistance and high blood glucose levels in early pregnancy alter the functioning of the placenta in ways that persistently affect the supply of nutrients and fat in the unborn baby. There is an increasing focus on the need to optimise preconception nutrition but as yet, limited preconception interventions that are recognized as promoting health for the mother and her child.
The Investigators will recruit up to 1800 women, aged 18-38 years, who are planning a pregnancy in the United Kingdom, Singapore and New Zealand with the aim of securing 600 or more pregnancies. The participants will be randomly allocated to receive the standard nutritional drink or the study nutritional drink. Women who conceive between one and twelve months after starting the nutritional drink will be followed through pregnancy and studied with their babies for three years after delivery. Various testing will be carried out at relevant time points. Mothers will undergo blood, urine, hair and cheek swab sampling, dual-energy X-ray absorptiometry (DXA) scans along with body measurements and health and lifestyle questionnaires. Infants will undergo hair, cheek swab, urine and stool sampling along with body measurements, measurements of body composition and a DXA scan. Placental, cord and other perinatal tissues/samples will be collected.
The data collected will allow identification of the contributions of nutritional and lifestyle factors, social and economic status, ethnicity, genetics and metabolomics and gut microbes to maintaining healthy glucose metabolism in pregnancy, enhancing fertility, mood and reproductive outcomes in the mother, and promoting healthy growth, body composition and wellbeing in the children.
The effect of the intervention on the primary outcome will be examined in two special interest groups; i) women who are overweight or obese prior to conception & ii) women with documented evidence of dysglycemia prior to conception.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention (study nutritional drink) | Experimental | Study nutritional drink comes in the form of a sachet to mix with water & take twice a day (once in the morning and once in the evening). The drink will be taken before the participant becomes pregnant (for up to 1 year) and throughout pregnancy. |
|
| Control (standard nutritional drink) | Active Comparator | Standard nutritional drink comes in the form of a sachet to mix with water & take twice a day (once in the morning and once in the evening). The drink will be taken before the participant becomes pregnant (for up to 1 year) and throughout pregnancy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Study nutritional drink | Dietary Supplement | Study nutritional drink containing a mix of micronutrients, probiotics and myo-inositol. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Glucose tolerance during pregnancy | Pregnancy Oral Glucose Tolerance Test (OGTT) measurement at 24 - 32 weeks gestation |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of gestation | Up to 43 weeks, derived from estimated date of conception from menstrual and ultrasound scan data and date of delivery | |
| Pregnancy weight gain and body composition | Up to 36 weeks, between date of first pregnancy visit and late gestation |
| Measure | Description | Time Frame |
|---|---|---|
| Health economics analysis (cost benefit analysis) | Composite analysis between preconception visit which is up to 1 year before pregnancy and infant age 3.5 years, assessed up to 5.5 years | |
| Offspring neurocognitive and behavioural development (behavioural and Ages & Stages questionnaires) |
Inclusion Criteria:
Exclusion Criteria:
The partners of the women (over 16 years of age) will also be invited to participate in the study. After having gained written informed consent, fathers will have blood, urine, hair sampling, cheek swabs and body measurements taken and will complete a health and a lifestyle questionnaire at one of the visits during pregnancy.
The mother will consent for their babies to have body measurements, buccal, hair, stool samples and allergy testing from birth to 3.5 years.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Wayne Cutfield, BHB MB ChB DCH MD FRACP | The University of Auckland | Principal Investigator |
| Shiao-Yng Chan, MBBChir (UK), FRCOG (UK), PhD | National University Hospital, Singapore | Principal Investigator |
| Keith Godfrey, BM PhD FRCP | MRC Lifecourse Epidemiology Unit, University of Southampton | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The University of Auckland | Auckland | 1142 | New Zealand | |||
| National University Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28320484 | Background | Godfrey KM, Cutfield W, Chan SY, Baker PN, Chong YS; NiPPeR Study Group. Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health ("NiPPeR"): study protocol for a randomised controlled trial. Trials. 2017 Mar 20;18(1):131. doi: 10.1186/s13063-017-1875-x. | |
| 41578268 |
| Label | URL |
|---|---|
| Study Website | View source |
Not provided
Not provided
| National University of Singapore |
| OTHER |
| Nestec Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
| Standard nutritional drink | Dietary Supplement | Standard nutritional drink containing a mix of micronutrients. |
|
| Postpartum weight retention and body composition | Up to 2 years, between date of delivery and 6,12 and 24 months postpartum |
| Change in body composition before, during and after gestation | Up to 4 years, between preconception, pregnancy and 2 years postpartum |
| Clinical pregnancy, pregnancy loss and live birth rates, including median time to conception of those who conceive during the treatment period and proportions conceiving within 3 months, 6 months and a year of commencing the NiPPeR drink | Between recruitment and delivery |
| Gestational diabetes frequency | Pregnancy OGTT measurement at 24 - 32 weeks gestation |
| Hypertensive disorders of pregnancy (pregnancy-induced hypertension and pre-eclampsia/eclampsia) | Up to 49 weeks, between conception derived from estimated date of conception from menstrual and ultrasound scan data and date of delivery, and up to 6 weeks after delivery |
| Nausea and vomiting frequency | Up to 36 weeks, between 7 weeks of gestation and delivery |
| Other antenatal, perinatal and postnatal complications | Up to 49 weeks, between conception from estimated date of conception derived from menstrual and ultrasound scan data, and up to 6 weeks after delivery |
| Preconception and antenatal maternal wellbeing/mood (Edinburgh Post-natal Depression Scale and State-Trait Anxiety Inventory) | Up to 2 years, between preconception and delivery |
| Postnatal maternal wellbeing/mood (Edinburgh Post-natal Depression Scale and State-Trait Anxiety Inventory) | Up to 52 weeks, between date of delivery and infant age 1 year |
| Mode of labour onset and delivery | Delivery |
| Neonatal complications and admission to neonatal care facilities | Up to 4 weeks post-delivery |
| Preconception maternal micronutrient status (blood analysis) | Date of second preconception visit up to 1 year before pregnancy |
| Antenatal maternal micronutrient status (blood analysis) | Up to 30 weeks, between 7 weeks gestation and 37 weeks of gestation |
| Preconception maternal gut microbiota composition and activity profile (analysis of sequencing and transcription data) | Up to 6 weeks from the start of intervention, date of preconception visit 2 which is up to 1 year before pregnancy |
| Antenatal and postnatal maternal gut and epithelial microbiota composition profile (analysis of sequencing data) | Up to 18 months, between 7 weeks gestation and post-delivery visits |
| Maternal preconception biochemical, metabolic and molecular profiles | Up to 6 weeks from the start of intervention, date of second preconception visit which is up to 1 year before pregnancy |
| Maternal antenatal biochemical, metabolic and molecular profiles | Up to 30 weeks, between 7 weeks gestation and 37 weeks of gestation |
| Placental and cord tissue, and their cellular derivatives: biochemical, metabolic and molecular profiles | Birth |
| Maternal postnatal biochemical, metabolic and molecular profiles | 6 months after delivery |
| Maternal preconception epigenetic profile | Preconception to up to 1 year before pregnancy |
| Maternal antenatal epigenetic profile | Up to 30 weeks, between 7 weeks gestation and 37 weeks of gestation |
| Maternal postnatal epigenetic profile | 6 months after delivery |
| Breast milk macronutrient profile (subsample) | Up to 1 year, between date of delivery and 1 year postpartum |
| Breast milk micronutrient profile (subsample) | Up to 1 year, between date of delivery and 1 year postpartum |
| Breast milk immune factor profile (subsample) | Up to 1 year, between date of delivery and 1 year postpartum |
| Breast milk epigenetic profile (subsample) | Up to 1 year, between date of delivery and 1 year postpartum |
| Breast milk biochemical, metabolic, microbiome and molecular profiles (subsample) | Up to 1 year, between date of delivery and 1 year postpartum |
| Healthy lactogenesis | Up to 1 year, between date of delivery and 1 year postpartum |
| Maternal and infant transcriptomics (including of breastmilk) | Up to 34 months, between preconception, pregnancy and 1 year postpartum |
| Intrauterine growth and wellbeing as assessed by antenatal serial ultrasound scans | Up to 30 weeks, between 7 weeks gestation and 37 weeks of gestation |
| Offspring birthweight and size at birth | At birth |
| Offspring size for gestational age at birth, less than the 10th, 10th - 90th, and above the 90th percentiles for gestational age | At birth |
| Offspring size for gestational age and sex at birth (percentile and standard deviation scores) | At birth |
| Offspring adiposity (skinfold thicknesses, regional, total and percentage fat mass) | Up to 3.5 years, between date of delivery and 3.5 years postpartum |
| Adiposity gain, body composition and linear growth during infancy and childhood | Up to 3.5 years, from birth to infant age 3.5 years |
| Cord blood C-peptide | At delivery |
| Offspring cardiometabolic profile | Up to 3.5 years, from birth to infant age 3.5 years |
| Offspring allergic wellbeing | Up to 3.5 years, from birth to infant age 3.5 years |
| Offspring biochemical, metabolic and molecular profiles | Up to 3.5 years, from birth to infant age 3.5 years |
| Offspring epigenetic profile | Up to 3.5 years, from birth to infant age 3.5 years |
| Infant gut microbiota composition and activity | Up to 3.5 years, from birth to infant age 3.5 years |
| Influence of parental and offspring genotype, sociodemography, body composition, metabolism, lifestyle and diet on the above primary and secondary outcomes at baseline and with the intervention | Up to 5.5 years, between preconception, pregnancy and 3.5 years postpartum |
| Up to 3.5 years, from birth to infant age 3.5 years |
| Offspring respiratory development (absence of respiratory symptoms) | Up to 3.5 years, from birth to infant age 3.5 years |
| Offspring allergic development (clinical evaluation of atopic disorders and skin prick test reaction diameter) | Up to 3.5 years, from birth to infant age 3.5 years |
| Offspring health and wellbeing (questionnaires) | Up to 3.5 years, from birth to infant age 3.5 years |
| Maternal health and wellbeing | Up to 4 years, between preconception visit which is up to 1 year before pregnancy and up to 2 years after delivery |
| Singapore |
| 119074 |
| Singapore |
| University Hospital Southampton NHS Foundation Trust | Southampton | Hampshire | SO16 6YD | United Kingdom |
| Lai JS, Lim SX, Barton SJ, Tham EH, El-Heis S, Albert BB, Childs CE, Conlon CA, Colega MT, Cox V, Nield H, Loy SL, Cutfield WS, Chong MF, Godfrey KM, Chan SY. Preconception dietary patterns and time-to-conception in the high-income multi-country NiPPeR study. Nutr J. 2026 Jan 23;25(1):23. doi: 10.1186/s12937-026-01283-0. |
| 38411017 | Derived | Han SM, Huang F, Derraik JGB, Vickers MH, Devaraj S, Redeuil K, Campos-Gimenez E, Pang WW, Godfrey KM, Chan SY, Thakkar SK, Cutfield WS; NiPPeR Study Group. A nutritional supplement during preconception and pregnancy increases human milk vitamin D but not B-vitamin concentrations. Clin Nutr. 2023 Dec;42(12):2443-2456. doi: 10.1016/j.clnu.2023.09.009. Epub 2023 Oct 5. |
| 38287349 | Derived | Lyons-Reid J, Derraik JGB, Kenealy T, Albert BB, Ramos Nieves JM, Monnard CR, Titcombe P, Nield H, Barton SJ, El-Heis S, Tham E, Godfrey KM, Chan SY, Cutfield WS; NiPPeR Study Group. Impact of preconception and antenatal supplementation with myo-inositol, probiotics, and micronutrients on offspring BMI and weight gain over the first 2 years. BMC Med. 2024 Jan 30;22(1):39. doi: 10.1186/s12916-024-03246-w. |
| 38051700 | Derived | Godfrey KM, Titcombe P, El-Heis S, Albert BB, Tham EH, Barton SJ, Kenealy T, Chong MF, Nield H, Chong YS, Chan SY, Cutfield WS; NiPPeR Study Group. Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial. PLoS Med. 2023 Dec 5;20(12):e1004260. doi: 10.1371/journal.pmed.1004260. eCollection 2023 Dec. |
| 37915619 | Derived | Han SM, Derraik JGB, Vickers MH, Devaraj S, Huang F, Pang WW, Godfrey KM, Chan SY, Thakkar SK, Cutfield WS; NiPPeR Study Group. A nutritional supplement taken during preconception and pregnancy influences human milk macronutrients in women with overweight/obesity and gestational diabetes mellitus. Front Nutr. 2023 Oct 17;10:1282376. doi: 10.3389/fnut.2023.1282376. eCollection 2023. |
| 36866469 | Derived | Lyons-Reid J, Derraik JGB, Kenealy T, Albert BB, Nieves JMR, Monnard CR, Titcombe P, Nield H, Barton SJ, El-Heis S, Tham E, Godfrey KM, Chan SY, Cutfield WS. The effect of a preconception and antenatal nutritional supplement on children's BMI and weight gain over the first 2 years of life: findings from the NiPPeR randomised controlled trial. Lancet Glob Health. 2023 Mar;11 Suppl 1:S11-S12. doi: 10.1016/S2214-109X(23)00095-5. |
| 36754158 | Derived | Chan SY, Barton SJ, Loy SL, Chang HF, Titcombe P, Wong JT, Ebreo M, Ong J, Tan KM, Nield H, El-Heis S, Kenealy T, Chong YS, Baker PN, Cutfield WS, Godfrey KM; NiPPeR Study Group. Time-to-conception and clinical pregnancy rate with a myo-inositol, probiotics, and micronutrient supplement: secondary outcomes of the NiPPeR randomized trial. Fertil Steril. 2023 Jun;119(6):1031-1042. doi: 10.1016/j.fertnstert.2023.01.047. Epub 2023 Feb 6. |
| 36704795 | Derived | Han SM, Devaraj S, Derraik JGB, Vickers MH, Huang F, Dubascoux S, Godfrey KM, Chan SY, Pang WW, Thakkar SK, Cutfield WS; NiPPeR Study Group. A nutritional supplement containing zinc during preconception and pregnancy increases human milk zinc concentrations. Front Nutr. 2023 Jan 10;9:1034828. doi: 10.3389/fnut.2022.1034828. eCollection 2022. |
| 36628060 | Derived | Lim SX, Cox V, Rodrigues N, Colega MT, Barton SJ, Childs CE, Conlon CA, Wall CR, Cutfield WS, Chan SY, Godfrey KM, Chong MF; NiPPeR Study Group. Evaluation of Preconception Dietary Patterns in Women Enrolled in a Multisite Study. Curr Dev Nutr. 2022 Jun 25;6(7):nzac106. doi: 10.1093/cdn/nzac106. eCollection 2022 Jul. |
| 33782086 | Derived | Godfrey KM, Barton SJ, El-Heis S, Kenealy T, Nield H, Baker PN, Chong YS, Cutfield W, Chan SY; NiPPeR Study Group. Myo-Inositol, Probiotics, and Micronutrient Supplementation From Preconception for Glycemia in Pregnancy: NiPPeR International Multicenter Double-Blind Randomized Controlled Trial. Diabetes Care. 2021 May;44(5):1091-1099. doi: 10.2337/dc20-2515. Epub 2021 Mar 29. |
| ID | Term |
|---|---|
| D006943 | Hyperglycemia |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided